A new study suggests that prostate-specific membrane antigen positron emission tomography/computed tomography may be a highly beneficial tool for initial staging of high-risk and high-intermediate-risk prostate cancer.
The introduction of an autologous cellular immunotherapy began a paradigm shift in the treatment of metastatic castrate-resistant prostate cancer (mCRPC). That was in 2010. This Urology Times Partner Perspective offers practical considerations for the use of immunotherapy in mCRPC
Read More
Read More